{
    "id": 25430,
    "fullName": "EPAS1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EPAS1 indicates the presence of the EPAS1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2034,
        "geneSymbol": "EPAS1",
        "terms": [
            "EPAS1",
            "bHLHe73",
            "ECYT4",
            "HIF2A",
            "HLF",
            "MOP2",
            "PASD2"
        ]
    },
    "variant": "positive",
    "createDate": "09/26/2016",
    "updateDate": "07/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8528,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, a clear cell renal cell carcinoma patient harboring a VHL mutation, with a tumorgraft that had demonstrated Epas1 (Hif2a) expression in 70% of tumor cells and sensitivity to a Hif2a antagonist, was progression-free for greater than 11 months following treatment with PT2385 (PMID: 27595394).",
            "molecularProfile": {
                "id": 26349,
                "profileName": "EPAS1 pos VHL inact mut"
            },
            "therapy": {
                "id": 4146,
                "therapyName": "PT2385",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6674,
                    "pubMedId": 27595394,
                    "title": "Targeting renal cell carcinoma with a HIF-2 antagonist.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595394"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9002,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Gilenya (fingolimod) resulted in a transient decrease in expression of Hif1a and Epas1 (Hif2a), circulating VEGF levels, remodeling of blood vessels, reduced proliferation, and increased tumor cell death, but was not associated with significant tumor growth inhibition in a VHL wild-type renal clear cell carcinoma cell line xenograft model (PMID: 27507852).",
            "molecularProfile": {
                "id": 26654,
                "profileName": "EPAS1 pos HIF1A pos"
            },
            "therapy": {
                "id": 3610,
                "therapyName": "Fingolimod",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6849,
                    "pubMedId": 27507852,
                    "title": "FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27507852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9003,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilenya (fingolimod) sensitized a Hif1a and Epas1(Hif2a)-expressing renal clear cell carcinoma cell line xenograft model to Gemzar (gemcitabine), resulting in decreased tumor volume (PMID: 27507852).",
            "molecularProfile": {
                "id": 26654,
                "profileName": "EPAS1 pos HIF1A pos"
            },
            "therapy": {
                "id": 4857,
                "therapyName": "Fingolimod + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6849,
                    "pubMedId": 27507852,
                    "title": "FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27507852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26349,
            "profileName": "EPAS1 pos VHL inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26350,
            "profileName": "EPAS1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26654,
            "profileName": "EPAS1 pos HIF1A pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}